To study the association between PPAR-γ gene polymorphism and psoriasis vulgaris in Egyptian patients to explore if this polymorphism influenced disease risk or clinical presentation.
There was significant decrease in CXCL 12 expression in the keratinocytes of psoriasis vulgaris patients after MTX therapy than before treatment, P-value was 0.009.
Here, we show that CRNN expression was increased in the lesioned epidermis from the patients with psoriasis vulgaris and skin lesions from the imiquimod (IMQ)-treated mice.
The expression levels of IL-35, IL-36γ and CCL27 in peripheral blood were analyzed statistically.<b>Results:</b> The expression of IL-35 in the peripheral blood of the pre-PV group (187.54 ± 172.41) was significantly lower than that of the control group (310.52 ± 174.22) and the PV treatment group (417.75 ± 47.07).
Leakage of sweat as evidenced by the immunohistochemical detection of dermcidin was specifically observed around the acrosyringium of these "cold spots" in LP, but not PsV, lesions and associated with CXCL10 induction on neighboring keratinocytes and syringotropic migration of CXCR3<sup>+</sup> T cells.
There was a significant increase in the serum levels of Galectin 3 and decrease in PASI scores after 3 months of treatment with NB-UVB phototherapy in patients with psoriasis Vulgaris (<i>p</i> value < .001).
The study aimed at adding more insight on the role played by co-inhibitory molecule BTLA in psoriasis vulgaris and its inter-relation with RORγt and IL-7 to establish a basis for novel treatment strategies.
There were significant reductions in the serum levels of YKL-40 and PASI scores after 3 months of treatment with NB-UVB phototherapy in patients with psoriasis vulgaris (<i>p</i> value<.001).
Psoriasis vulgaris concurrence was lowest in PPP (15.8% vs 54.4% in GPP and 46.2% in ACH, P < .0005 for both), whereas the mean age of onset was earliest in GPP (31.0 vs 43.7 years in PPP and 51.8 years in ACH, P < .0001 for both).
In this study, we investigated the expression patterns of GLUT1 in keratinocytes in the human psoriasis vulgaris and imiquimod-induced psoriasis model, and determined that the glucose metabolism inhibitor 2-deoxy-D-glucose (2-DG) can relieve the psoriatic lesions.
The study aimed at adding more insight on the role played by co-inhibitory molecule BTLA in psoriasis vulgaris and its inter-relation with RORγt and IL-7 to establish a basis for novel treatment strategies.
The study aimed at adding more insight on the role played by co-inhibitory molecule BTLA in psoriasis vulgaris and its inter-relation with RORγt and IL-7 to establish a basis for novel treatment strategies.
The nuclear factor erythroid 2⁻related factor 2 (Nrf2) and its regulators were increased in both forms of psoriasis while heme oxygenase 1 levels were increased only in psoriasis vulgaris.
The mean serum P-SEP levels in patients with PV, PsA, and GPP were 144.9 pg/mL (25th-75th percentile; 78-181), 168.1 pg/mL (124-203), and 479.9 pg/mL (216-581), respectively.
The aim of this study was to investigate serum concentrations of AhR, cytochromes P450 (CYP) 1A1 and 1B1 in patients with exacerbated psoriasis vulgaris treated with combined therapy of ultraviolet radiation (UVR) and crude coal tar.
In addition, immunofluorescent staining revealed more BDCA-2 and CD123 double-positive plasmacytoid dendritic cell infiltration into the dermis than that of psoriasis vulgaris.
The mean serum P-SEP levels in patients with PV, PsA, and GPP were 144.9 pg/mL (25th-75th percentile; 78-181), 168.1 pg/mL (124-203), and 479.9 pg/mL (216-581), respectively.
The association of ERAP1 and ERAP2 single nucleotide polymorphisms and their haplotypes with psoriasis vulgaris is dependent on the presence or absence of the HLA-C*06:02 allele and age at disease onset.
The mean serum P-SEP levels in patients with PV, PsA, and GPP were 144.9 pg/mL (25th-75th percentile; 78-181), 168.1 pg/mL (124-203), and 479.9 pg/mL (216-581), respectively.